71 / 320
635
2010;54:1111-6.
13. MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics
of antipsuedomonal cephalosporins in patients with ventilator
associated
pneumonia.
Antimicrob
Agents
Chemother
2014;58:1359-64.
14. Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. Comparative
in vivo efficacy of meropenem, imipenem, and cefepime against
Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux
pumps. Diagn Microbiol Infect Dis 2007;57:153-61.
15. MacVane SH, Kuti JL, Nicolau DP. Prolonging beta-lactam
infusion: a review of the rationale and evidence, and guidance for
implementation. Int J Antimicrob Agents 2014;43:105-13.
16. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of
piperacillin-tazobactam for the treatment of Pseudomonas
aeruginosa infections: prolonged or continuous infusion?
Pharmacotherapy 2007;27:1490-7.
17. Lodise TP Jr, Lomaestro BM, Drusano GL. Piperacillin-tazobactam
for Pseudomonas aeruginosa infection: clinical implications of an
extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-
63.
18. Grupper M, Kuti JL, Nicolau DP. Continuous and prolonged
intravenous beta-lactam dosing: implications for the clinical
laboratory. Clin Microbiol Rev 2016;29:759-72.
19. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of
beta-lactam antibiotics in severe sepsis: a multicenter, double-
blind, randomized controlled trial. Clin Infect Dis 2013;56:236-
44.
20. Dulhunty JM, Roberts JA, Davis JS, et al. A multicenter randomized
trial of continuous versus intermittent beta-lactam infusion in
severe sepsis. Am J Respir Crit Care Med 2015;192:1298-305.
21. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application
of fluoroquinolone pharmacodynamics. J Antimicrob Chemother
2000;46:669-83.
22. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag
JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill
patients. Antimicrob Agents Chemother 1993;37:1073-81.
23. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce
PF. Pharmacodynamics of fluoroquinolones against Streptococcus
pneumoniae in patients with community-acquired respiratory
tract infections. Antimicrob Agents Chemother 2001;45:2793-7.
24. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn
J. Relationship between fluoroquinolone area under the curve:
minimum inhibitory concentration ratio and the probability
of eradication of the infecting pathogen, in patients with
nosocomial pneumonia. J Infect Dis 2004;189:1590-7.
25. Deryke CA, Kuti JL, Nicolau DP. Re-evaluation of current
susceptibility breakpoints for Gram-negative rods based on
pharmacodynamic assessment. Diagn Microbiol Infect Dis
2007;58:337-44.
26. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin
therapeutic
guidelines:
a
summary
of
consensus
recommendations from the Infectious Diseases Society of
America, the American Society of Health-System Pharmacists,
and the Society of Infectious Diseases Pharmacists. Clin Infect Dis
2009;49:325-7.
27. Neely MN, Youn G, Jones B, et al. Are vancomycin trough
concentrations adequate for optimal dosing? Antimicrob Agents
Chemother 2014;58:309-16.
28. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by
the Infectious Diseases Society of America for the treatment of
methicillin-resistant Staphylococcus aureus infections in adults
and children. Clin infect Dis 2011;52:1-38.
29. Koomanachai P, Kim A, Nicolau DP. Pharmacodynamic evaluation
of tigecycline against Acinetobacter baumannii in a murine
pneumonia model. J Antimicrob Chemother 2009;63:982-7.
30. Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and
patient-specific response determinants in patients with hospital-
acquired pneumonia treated with tigecycline. Antimicrob Agents
Chemother 2012;56:1065-72.
31. Cheng A, Chuang YC, Sun HY, et al. Excess mortality associated
with colistin-tigecycline compared with colistin-carbapenem
combinationtherapy for extensively drug-resistant Acinetobacter
baumannii bacteremia: a multicenter prospective observational
study. Crit Care Med 2015;43:1194-204.
32. De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline
in critically ill patients with severe infections due to multidrug-
resistant bacteria. Crit Care 2014;18:R90.
33. Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics
and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn
Microbiol Infect Dis 2012;74:213-23.
34. Garonzik SM, Li J, Thamlikitkul V, et al. Population
pharmacokinetics of colistin methanesulfonate and formed
colistin in critically ill patients from a multicenter study provide
dosing suggestions for various categories of patients. Antimicrob
Agents Chemother 2011;55:3284-94.
35. Nation RL, Garonzik SM, Li J, et al. Updated US and European
dose recommendations for intravenous colistin: how do they
perform? Clin Infect Dis 2016;62:552-8.
36. Sandri AM, Landersdorfer CB, Jacob J, et al. Population
pharmacokinetics of intravenous polymyxin B in critically ill
patients: implications for selection of dosage regimens. Clin
Infect Dis 2013;57:524-31.
37. Nelson BC, Eiras DP, Gomez-Simmonds A, et al. Clinical
outcomes associated with polymyxin B dose in patients with
bloodstream infections due to carbapenem-resistant Gram-
negative rods. Antimicrob Agents Chemother 2015;59:7000-6.
38. Cheah SE, LiJ, Tsuji B, Forrest A, Bulitta JB, Nation RL. Colistin
and polymyxin B dosage regimens against Acinetobacter
baumannii: differences in activity and the emergence of
resistance. Antimicrob Agents Chemother 2016;60:3921-33.
39. Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-
based clinical pathway for empiric antibiotic choice in patients
with ventilator-associated pneumonia. J Crit Care 2010;25:69-
77.
40. Nicasio Am, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay
and hospital costs associated with a pharmacodynamic-based
clinical pathway for empiric antibiotic choice for ventilator-
associated pneumonia. Pharmacotherapy 2010;30:453-62.
[TRADUCCIÓN. CÓMO OPTIMIZAR LA FARMACODINÁMICA ANTIMICROBIANA: UNA GUÍA UN PROGRAMA DE OPTIMIZACIÓN... - Joseph L. Kuti, PharmD]